Advertisement


Robert J. Motzer, MD, on Renal Cell Carcinoma: New Results With Nivolumab and Ipilimumab

ESMO Congress 2022

Advertisement

Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the CheckMate 914 trial, which explored the efficacy of adjuvant nivolumab plus ipilimumab vs placebo in the treatment of patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (Abstract LBA4).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The CheckMate 914 trial compared nivolumab plus ipilimumab to placebo in patients who had undergone a nephrectomy for clear cell carcinoma and were at substantial risk of recurrence. The eligibility included patients who were pT2a high grade, any pT2b, any pT3, pT4, or N1 positive disease, and the patients were randomized one to one to Nivolumab, 240 mg IV every two weeks for 12 doses, ipilumumab 1 mg/kg IV every six weeks for four doses or matched placebo. The expected treatment duration of this study was six months. The trial randomized over 800 patients and the patient characteristics were quite balanced. The majority of patients, nearly 80%, fell into the pT3a category. The primary endpoint of the trial was disease-free survival by blind, independent central review, and at the time of the analysis, the trial did not reach the primary endpoint. The hazard ratio for comparison between the two arms was 0.92, and the P value was 0.53. The 24-month disease-free survival rate was 76% for NIVO plus IPI, and 74% for placebo. The adverse event profile for NIVO plus IPI was similar to that, which we had seen in the studying of advanced disease. However, few patients, relatively few, completed the full 12 courses of NIVO and four of IPI, only 57%. The proportion of patients that had treatment-related grade three or higher AEs was 28% for NIVO plus IPI, compared to 2% per placebo. This is actually a lower rate than we saw for NIVO plus IPI in the setting of metastatic disease, but the treatment discontinuation rate was relatively high in this trial in the adjuvant setting. Treatment adverse events were as expected. The most common was pruritus, fatigue, and diarrhea, as we'd expect for NIVO plus IPI, and the proportion of patients who required high dose steroids on this NIVO plus IPI program was 23%. In summary then, part A of CheckMate 914 trial, which compares NIVO plus IPI to placebo in patients with localized RCC at high risk of post-nephrectomy relapse did not meet the primary endpoint of disease-free survival. The safety profile of NIVO plus IPI was consistent with the known profile for the combination of advanced RCC. However, the rate of discontinuation due to treatment-related adverse events was considerable with NIVO plus IPI in the adjuvant setting. Further analysis underway to understand the outcome of CheckMate 914 with regard to the patient population studied, and there is a part B, which is essentially a separate trial that has a primary endpoint of comparing NIVO monotherapy to placebo. That study is ongoing.

Related Videos

Prostate Cancer

Neal D. Shore, MD, on Prostate Cancer: Biomarker Analysis, Enzalutamide, and Active Surveillance

Neal D. Shore, MD, of Carolina Urologic Research Center/Genesis Care, discusses new data from the ENACT trial, which showed that patients with prostate cancer and the RNA biomarkers PAM50 and AR-A were likely to have better outcomes with enzalutamide treatment. The results suggest that such RNA biomarkers may help to identify patients who may benefit from enzalutamide treatment compared with active surveillance (Abstract 1385P).

Skin Cancer
Immunotherapy

Georgina V. Long, MD, PhD, on Melanoma: Findings on Circulating Tumor DNA, Disease Recurrence, and Immunotherapy

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, discusses results from the CheckMate 915 trial, an analysis of the pretreatment circulating tumor DNA, along with other clinical and translational baseline factors, and their association with disease recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy (Abstract 788O).

Lung Cancer
Immunotherapy

Gérard Zalcman, MD, PhD, on Non–Small Cell Lung Cancer: Phase III Trial Findings on Nivolumab and Ipilimumab

Gérard Zalcman, MD, PhD, of France’s Bichat-Claude Bernard Hospital, Assistance Publique–Hôpitaux de Paris, discusses phase III results from the IFCT-1701 trial, which explored the questions of whether to administer nivolumab plus ipilimumab for 6 months or whether to prolong the treatment in patients with advanced non–small cell lung cancer (Abstract 972O).

Lung Cancer

Charles Swanton, PhD, on Non–Small Cell Lung Cancer Induced by Air Pollution

Charles Swanton, PhD, of The Francis Crick Institute, discusses a newly discovered mechanism of action for air pollution–induced non–small cell lung cancer in which particles linked to climate change appear to promote cancerous changes. The finding might pave the way for new potential approaches to lung cancer prevention and treatment (Abstract LBA1).

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Recent Phase III Data on Cabozantinib, Nivolumab, and Ipilimumab From the COSMIC-313 Trial

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss phase III findings showing that cabozantinib in combination with nivolumab and ipilimumab reduced the risk of disease progression or death compared with the combination of nivolumab plus ipilimumab in patients with previously untreated advanced renal cell carcinoma of IMDC (the International Metastatic RCC Database Consortium) intermediate or poor risk. However, the combination of cabozantinib, nivolumab, and ipilimumab vs nivolumab plus ipilimumab did not demonstrate an overall survival benefit to patients (Abstract LBA8).

Advertisement

Advertisement




Advertisement